Q2 2025 Kura Oncology Inc Earnings Call Transcript
Key Points
- Kura Oncology Inc (KURA) presented positive monotherapy data from the KOMET-001 trial at ASCO, showing promising results for ziftomenib in relapsed or refractory NPM1 mutated AML.
- The FDA accepted Kura's NDA for ziftomenib, granting priority review with a PDUFA target action date of November 30, 2025.
- Kura is actively preparing for potential approval by building commercial supply and quality systems, advancing pre-approval inspection readiness, and recruiting and training their sales force.
- Kura's partnership with Kyowa Kirin is bolstering the global development and commercialization of ziftomenib, with alignment on advancing both relapsed refractory and frontline programs.
- Kura had $630.7 million in cash, cash equivalents, and short-term investments as of June 30, 2025, providing a strong financial position to support ongoing development and commercialization efforts.
- Research and development expenses increased significantly to $62.8 million for the second quarter of 2025, up from $39.7 million in the same period of 2024.
- General and administrative expenses also rose to $25.2 million for the second quarter of 2025, compared to $16.7 million in the second quarter of 2024, primarily due to pre-commercial activities.
- Net loss for the second quarter of 2025 was $66.1 million, compared to a net loss of $50.8 million for the second quarter of 2024.
- There is a risk of competition in the menin inhibitor space, with other companies also advancing their programs, potentially impacting market share.
- The timeline for pivotal program data readouts is projected for 2028, which may be seen as a long wait for investors looking for quicker returns.
Hello, and welcome, everyone joining today's second-quarter 2025 Kura Oncology Inc. financial results conference call. (Operator Instructions) Please note this call is being recorded.
I am standing by should you need any assistance. It is now my pleasure to turn the meeting over to Greg Mann, SVP of Investor Relations and Corporate Affairs. Please go ahead.
Thank you, Brittany. Good afternoon and welcome to Kura Oncology's second-quarter 2025 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Dr. Mollie Leoni, Chief Medical Officer; Brian Powl, Chief Commercial Officer; and Tom Doyle, Senior Vice President of Finance and Accounting.
Before I turn the call over to Dr. Wilson, we remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today, and may involve risks and uncertainties that cause actual results to differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
